The $4.6 billion worldwide market for knee arthroplasty is technologically mature, but it is underpenetrated today and it's still growing at a robust 14% annual rate. Furthermore, changes in demographics and patient expectations have created a large, unmet clinical need: the 50-something year old with unbearable knee pain. Today, that is the focus of a great deal of technological innovation-most of it incremental-on the part of large companies that seek to increase the longevity of devices with wear-resistant materials, and technologies that improve device fit, or the precision of placement and the accuracy of alignment of implants. But recently, and somewhat surprisingly, venture-backed start-ups have also begun to enter joint reconstruction with their own technological solutions. Four new companies believe they've staked out spaces ranging from operating alongside multi-billion dollar companies without facing crushing competition from them, to taking a more head-on competitive posture, and in each case, to make a clinical difference.
By Mary Stuart
The spine industry has recently been enjoying a rapid pace of technological innovation and a frenzy of new company creation,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.